Please assess the completion status of the following clinical trial:

Trial Title: The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Patient seeks consultation for lack of satisfactory symptom response to once daily PPIs.~2. Age≥ 21 years old.~3. Abnormal distal esophageal pH determined by total % time pH \<4 or DeMeester Score. Testing to be completed off GERD medications for at least 7 days, with the exception of antacids, which may be taken up until the morning of assessment.~4. Suitable surgical candidate (i.e. is able to undergo general anesthesia and laparoscopic surgery).~5. Patient has provided written informed consent for participation in the randomized study.~Key Exclusion Criteria:~1. Currently taking double-dose PPIs (twice daily dosing).~2. Hiatal hernia \>3cm as determined by endoscopy.~3. Distal esophageal motility (average of sensors 3 and 4) is less than 35 mmHg peristaltic amplitude on wet swallows or \<70% (propulsive) peristaltic sequences.~4. Esophagitis Grade C or D (Los Angeles classification).~5. Body mass index \>35.~6. Diagnosed with an esophageal motility disorder LES.~7. Esophageal stricture or gross esophageal anatomic abnormalities~8. History of/or known Barrett's esophagus.~9. Suspected or known allergies to titanium, stainless steel, nickel or ferrous materials.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: ACTIVE_COMPARATOR): Double-dose PPI \[Omeprazole 20 mg BID (twice a day)\]
- Treatment Arm (Type: ACTIVE_COMPARATOR): LINX Reflux Management System

Based on this trial design, predict the completion outcome and termination type (if applicable).